转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析

目的:探讨影响转移性去势抵抗性前列腺癌(mCRPC)患者多西他赛化疗后总生存期(OS)的预后因素。方法:选择性回顾性分析96例接受多西他赛化疗的mCRPC患者的临床资料,对相关的临床因素分别进行单因素及多因素分析。结果:96例患者中63例死亡,全组患者中位OS为26.2个月。单因素分析显示,ECOG评分、基线前列腺特异抗原(PSA)值、骨转移、基线碱性磷酸酶(ALP)浓度及化疗周期数与化疗后OS相关(P<0.05)。多因素分析显示,基线ALP浓度≥120 IU/L、基线PSA值≥60 ng/mL、化疗周期数<10是较短OS的独立预后因素(P<0.05)。结论:多西他赛治疗mCRPC可以获得较好的总生存率,化疗前基线ALP浓度、基线PSA值及化疗周期数是影响预后的独立因素。

Prognostic analysis of metastatic castration-resistant prostate cancer patients treated with docetaxel-based thermotherapy

Objective： To investigate clinicopathological factors in predicting overall survival （OS） in patients with metastatic castration- resistant prostate cancer （mCRPC） treated with docetaxel-based thermotherapy. Methods： This study analyzed the clinicopathologic data of 96 consecutive patients with mCRPC who received doeetaxel chemotherapy. These clinicopathological factors were analyzed by univari- ate and multivariate Cox regression analysis. Results： During the follow-up period, 63 of 96 patients died and the median OS was 26.2 months. Univariate analysis identified ECOG PS, baseline ALP value, baseline PSA value, bone metastasis and treatment cycle as signifi- cant predictors of OS （P〈0.05）. Subsequent multivariate analysis reserved baseline ALP〉 120 IU/L, baseline PSA 〉60 ng/mL and treat- ment eycle〈10 as independent prognostic factors for shorter OS （P〈0.05）. Conclusion： The baseline ALP value, baseline PSA value and treatment cycle could provide independent prognostic indication of OS in Chinese patients with mCRPC treated with docetaxel.